After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

A small-scale artificial-intelligence model that learns from only a limited pool of data is exciting researchers for its potential to boost reasoning abilities. The model, known as Tiny Recursive ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.

I’d like to contribute a Sudoku Solver algorithm using the Backtracking technique. This algorithm systematically explores all valid placements of digits in a 9×9 Sudoku grid until it finds a valid ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Knapsack raised $10 million from ...

Getting design and engineering teams on the same page about what digital product to create and how to build it continues to be a challenge. A lot of companies find themselves dealing with scattered ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Figure 1. Neural networks can store and recall information. In a recall task where the desired output pattern is identical to the input pattern, several patterns can ...

Another name for brute force is exhaustive search. In these algorithms you consider every possible solution in the solution domain to find the optimal solution. Depending on the type of problem that ...